"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 4 | 5 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 3 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 5 | 6 |
| 2003 | 2 | 7 | 9 |
| 2004 | 2 | 4 | 6 |
| 2005 | 0 | 4 | 4 |
| 2006 | 2 | 4 | 6 |
| 2007 | 1 | 4 | 5 |
| 2008 | 2 | 6 | 8 |
| 2009 | 3 | 8 | 11 |
| 2010 | 1 | 6 | 7 |
| 2011 | 0 | 11 | 11 |
| 2012 | 2 | 4 | 6 |
| 2013 | 0 | 9 | 9 |
| 2014 | 3 | 12 | 15 |
| 2015 | 5 | 9 | 14 |
| 2016 | 2 | 4 | 6 |
| 2017 | 3 | 6 | 9 |
| 2018 | 2 | 10 | 12 |
| 2019 | 7 | 4 | 11 |
| 2020 | 3 | 8 | 11 |
| 2021 | 1 | 6 | 7 |
| 2022 | 1 | 6 | 7 |
| 2023 | 1 | 4 | 5 |
| 2024 | 3 | 3 | 6 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025 Jan 16; 145(3):290-299.
-
Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies. Cancer. 2025 Jan 15; 131(2):e35713.
-
Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer. Sci Rep. 2025 Jan 07; 15(1):1061.
-
Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol. 2025 Mar; 100(3):402-407.
-
Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study-5 and Children's Oncology Group Study AREN0321. Pediatr Blood Cancer. 2025 Mar; 72(3):e31490.
-
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
-
Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL). J Geriatr Oncol. 2025 Jan; 16(1):102160.
-
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro Oncol. 2024 Nov 04; 26(11):2044-2060.
-
Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors. Clin Genitourin Cancer. 2024 Dec; 22(6):102242.
-
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 10 17; 391(15):1379-1389.